Literature DB >> 23930679

Current approaches for TYMS polymorphisms and their importance in molecular epidemiology and pharmacogenetics.

Aurea Lima1, Rita Azevedo, Hugo Sousa, Vítor Seabra, Rui Medeiros.   

Abstract

TS is critical for providing the requisite nucleotide precursors in order to maintain DNA synthesis and repair. Furthermore, it is an important target for several drugs such as 5-fluorouracil and methotrexate. However, several mechanisms of resistance to TS inhibitors have been explained as linked to TYMS overexpression. Some authors have described the relationship between genetic polymorphisms on TYMS, in particular rs34743033, rs2853542 and rs34489327, with the development of several diseases and with the clinical response to drug therapy and/or survival. Nevertheless, the obtained results described in the literature are controversial, which has lead to a search strategy to understand the impact of these polymorphisms on molecular epidemiology and pharmacogenetics. With the progress of these scientific areas, early identification of individuals at risk of disease along with improvement in the prediction of patients' outcome will offer a powerful tool for the translation of TYMS polymorphisms into clinical practice and individualization of treatments.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23930679     DOI: 10.2217/pgs.13.118

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  11 in total

1.  Effect of thymidylate synthase (TYMS) gene polymorphisms with methotrexate treatment outcome in south Indian Tamil patients with rheumatoid arthritis.

Authors:  Niveditha Muralidharan; Durga P Misra; Vikramraj K Jain; Vir Singh Negi
Journal:  Clin Rheumatol       Date:  2017-03-27       Impact factor: 2.980

Review 2.  Targeting nuclear thymidylate biosynthesis.

Authors:  James Chon; Patrick J Stover; Martha S Field
Journal:  Mol Aspects Med       Date:  2016-11-19

Review 3.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

4.  Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Authors:  Aurea Lima; Vítor Seabra; Sandra Martins; Ana Coelho; António Araújo; Rui Medeiros
Journal:  Mol Biol Rep       Date:  2014-02-20       Impact factor: 2.316

5.  Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.

Authors:  Abrar Al-Sheikh; Al-Motassem Yousef; Daniah Alshamaseen; Rand Farhad
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-10       Impact factor: 3.333

6.  Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?

Authors:  Aurea Lima; Miguel Bernardes; Rita Azevedo; Rui Medeiros; Vítor Seabra
Journal:  Int J Mol Sci       Date:  2015-06-16       Impact factor: 5.923

7.  Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients.

Authors:  Aurea Lima; Vítor Seabra; Miguel Bernardes; Rita Azevedo; Hugo Sousa; Rui Medeiros
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

8.  Genetic Polymorphisms of TYMS, MTHFR, ATIC, MTR, and MTRR Are Related to the Outcome of Methotrexate Therapy for Rheumatoid Arthritis in a Chinese Population.

Authors:  Shuang Lv; HuiZhen Fan; Jiang Li; Hui Yang; Jing Huang; XiaoMing Shu; Lu Zhang; Yuan Xu; Xiaoya Li; Jieyu Zuo; Cheng Xiao
Journal:  Front Pharmacol       Date:  2018-11-28       Impact factor: 5.810

9.  Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.

Authors:  Nikola Kotur; Jelena Lazic; Bojan Ristivojevic; Biljana Stankovic; Vladimir Gasic; Lidija Dokmanovic; Nada Krstovski; Goran Milosevic; Dragana Janic; Branka Zukic; Sonja Pavlovic
Journal:  Genes (Basel)       Date:  2020-04-24       Impact factor: 4.096

10.  TYMS 3'-UTR Polymorphism: A Novel Association with FOLFIRINOX-Induced Neurotoxicity in Pancreatic Cancer Patients.

Authors:  Marina Emelyanova; Ilya Pokataev; Igor Shashkov; Elena Kopantseva; Vladimir Lyadov; Rustam Heydarov; Vladimir Mikhailovich
Journal:  Pharmaceutics       Date:  2021-12-29       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.